Form 4: Fractyl Health Director Clive Meanwell Granted Stock Options as Compensation

Fractyl Health, Inc. director Clive Meanwell was granted 22,500 stock options with an exercise price of $2.27 as part of his compensation for board service.

Summary

• Clive Meanwell, a director of Fractyl Health, Inc. (GUTS), was granted 22,500 stock options.
• The options have an exercise price of $2.27 per share.
• The grant date for these options was June 11, 2025.
• The options will expire on June 10, 2035.
• Vesting occurs in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 11, 2026), contingent on continued service as a non-employee director.
• This grant is compensation for his service on the board, consistent with the company's non-employee director compensation policy.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event for a director, which is generally a neutral to slightly positive signal as it aligns director interests with shareholders. There are no negative surprises.

Positives

• Aligns the director's interests with those of shareholders through equity ownership.
• Represents a standard compensation practice for non-employee directors, indicating adherence to established corporate governance policies.

Negatives

• Potential for minor dilution of existing shareholder equity upon exercise of the options.

Risks

• The value of the options is subject to the future performance of Fractyl Health's stock price.
• Vesting is contingent on continued service, meaning the director must remain on the board to realize the benefit.

Future Outlook

The document does not contain forward-looking statements or guidance beyond the vesting schedule of the granted options.

Industry Context

The grant of stock options to non-employee directors is a common practice across industries, particularly in the biotechnology and healthcare sectors where Fractyl Health operates. It serves to align the interests of board members with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of non-employee director compensation is a standard practice in the U.S. public company landscape, including the biotech industry. While specific grant sizes and exercise prices vary widely based on company size, stage, and individual director responsibilities, the mechanism itself is consistent with global benchmarks for corporate governance and executive/director incentives. No specific comparable companies or projects are mentioned in this filing to allow for a direct quantitative comparison.

Corporate Governance

Related Party Transactions

• The grant of 22,500 stock options to Clive Meanwell, a director of Fractyl Health, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of the options, but also increased alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will vest on the earlier of the next annual meeting of stockholders or June 11, 2026, subject to continued service.
• The director may exercise the vested options at any time before their expiration on June 10, 2035.

Key Dates

Keywords

Fractyl Health, GUTS, Clive Meanwell, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Non-employee Director